Top

Breast Cancer Research and Treatment

Published in:

01-04-2019 | Breast Cancer | Preclinical Study

Expression of Lamin A/C in early-stage breast cancer and its prognostic value

Authors: I. M. Alhudiri, C. C. Nolan, I. O. Ellis, A. Elzagheid, E. A. Rakha, Andrew R. Green, C. J. Chapman

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Abstract

Purpose

Lamins A/C, a major component of the nuclear lamina, play key roles in maintaining nuclear integrity, regulation of gene expression, cell proliferation and apoptosis. Reduced lamin A/C expression in cancer has been reported to be a sign of poor prognosis. However, its clinical significance in breast cancer remains to be defined. This study aimed to evaluate expression and prognostic significance of lamin A/C in early-stage breast cancer.

Methods

Using immunohistochemical staining of tissue microarrays, expression of lamin A/C was evaluated in a large well-characterised series of early-stage operable breast cancer (n = 938) obtained from Nottingham Primary Breast Carcinoma Series. Association of lamin A/C expression with clinicopathological parameters and outcome was evaluated.

Results

Positive expression rate of lamin A/C in breast cancer was 42.2% (n = 398). Reduced/loss of expression of lamin A/C was significantly associated with high histological grade (p < 0.001), larger tumour size (p = 0.004), poor Nottingham Prognostic Index score (p < 0.001), lymphovascular invasion (p = 0.014) and development of distant metastasis (p = 0.027). Survival analysis showed that reduced/loss of expression of lamin A/C was significantly associated with shorter breast cancer-specific survival (p = 0.008).

Conclusion

This study suggests lamin A/C plays a role in breast cancer and loss of its expression is associated with variables of poor prognosis and shorter outcome.

Lammerding J, Fong LG, Ji JY et al (2006) Lamins a and C but not lamin B1 regulate nuclear mechanics. J Biol Chem 281:25768–25780. https://doi.org/10.1074/jbc.M513511200 CrossRefPubMed

Butin-Israeli V, Adam SA, Goldman AE, Goldman RD (2012) Nuclear lamin functions and disease. Trends Genet 28:464–471. https://doi.org/10.1016/j.tig.2012.06.001 CrossRefPubMedPubMedCentral

Kong L, Schäfer G, Bu H et al (2012) Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway. Carcinogenesis 33:751–759. https://doi.org/10.1093/carcin/bgs022 CrossRefPubMed

Eckersley-Maslin MA, Bergmann JH, Lazar Z, Spector DL (2013) Lamin A/C is expressed in pluripotent mouse embryonic stem cells. Nucleus 4:53–60. https://doi.org/10.4161/nucl.23384 CrossRefPubMedPubMedCentral

Marmiroli S, Bertacchini J, Beretti F et al (2009) A-type lamins and signaling: the PI 3-kinase/Akt pathway moves forward. J Cell Physiol 220:553–561. https://doi.org/10.1002/jcp.21807 CrossRefPubMed

Jung H, Lee J, Yang S et al (2013) Nuclear lamins in the brain—new insights into function and regulation. Mol Neurobiol 47:290–301. https://doi.org/10.1007/s12035-012-8350-1.Nuclear CrossRefPubMed

Gerace L, Comeau C, Benson M (1984) Organization and modulation of nuclear lamina structure. J Cell Sci Suppl 1:137–160CrossRefPubMed

Ivorra C, Kubicek M, González JM et al (2006) A mechanism of AP-1 suppression through interaction of c-Fos with lamin A/C. Genes Dev 20:307–320. https://doi.org/10.1101/gad.349506 CrossRefPubMedPubMedCentral

Houben F, Willems CHMP, Declercq ILJ et al (2009) Disturbed nuclear orientation and cellular migration in A-type lamin deficient cells. Biochim Biophys Acta Mol Cell Res 1793:312–324. https://doi.org/10.1016/J.BBAMCR.2008.10.003 CrossRef

10.

Ho CY, Jaalouk DE, Vartiainen MK, Lammerding J (2013) Lamin A/C and emerin regulate MKL1-SRF activity by modulating actin dynamics. Nature 497:507–513. https://doi.org/10.1038/nature12105 CrossRefPubMedPubMedCentral

11.

Lee KK, Haraguchi T, Lee RS et al (2001) Distinct functional domains in emerin bind lamin A and DNA-bridging protein BAF. J Cell Sci 114:4567–4573PubMed

12.

Worman HJ (2012) Nuclear lamins and laminopathies. J Pathol 226:316–325. https://doi.org/10.1002/path.2999 CrossRefPubMed

13.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410CrossRef

14.

Zink D, Fische AH, Nickerson JA (2004) Nuclear structure in cancer cells. Nat Rev Cancer 4:677–687. https://doi.org/10.1038/nrc1430 CrossRef

15.

Solovei I, Wang AS, Thanisch K et al (2013) LBR and lamin A/C sequentially tether peripheral heterochromatin and inversely regulate differentiation. Cell 152:584–598. https://doi.org/10.1016/j.cell.2013.01.009 CrossRefPubMed

16.

Brachner A, Foisner R (2014) Lamina-associated polypeptide (LAP)2α and other LEM proteins in cancer biology. Adv Exp Med Biol 773:143–163. https://doi.org/10.1007/978-1-4899-8032-8_7 CrossRefPubMedPubMedCentral

17.

Qi Y-X, Yao Q-P, Huang K et al (2016) Nuclear envelope proteins modulate proliferation of vascular smooth muscle cells during cyclic stretch application. Proc Natl Acad Sci USA 113:5293–5298. https://doi.org/10.1073/pnas.1604569113 CrossRefPubMed

18.

Markiewicz E, Dechat T, Foisner R et al (2002) Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of retinoblastoma protein. Mol Biol Cell 13:4401–4413. https://doi.org/10.1091/mbc.E02-07-0450 CrossRefPubMedPubMedCentral

19.

Lin F, Worman HJ (1993) Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem 268:16321–16326PubMed

20.

Tilli CM, Ramaekers FC, Broers JL et al (2003) Lamin expression in normal human skin, actinic keratosis, squamous cell carcinoma and basal cell carcinoma. Br J Dermatol 148:102–109CrossRefPubMed

21.

Broers JL, Raymond Y, Rot MK et al (1993) Nuclear A-type lamins are differentially expressed in human lung cancer subtypes. Am J Pathol 143:211–220PubMedPubMedCentral

22.

Kaspi E, Frankel D, Guinde J et al (2017) Low lamin A expression in lung adenocarcinoma cells from pleural effusions is a pejorative factor associated with high number of metastatic sites and poor performance status. PLoS ONE 12:e0183136. https://doi.org/10.1371/journal.pone.0183136 CrossRefPubMedPubMedCentral

23.

Moss SF, Krivosheyev V, de Souza A et al (1999) Decreased and aberrant nuclear lamin expression in gastrointestinal tract neoplasms. Gut 45:723–729CrossRefPubMedPubMedCentral

24.

Prokocimer M, Margalit A, Gruenbaum Y (2006) The nuclear lamina and its proposed roles in tumorigenesis: projection on the hematologic malignancies and future targeted therapy. J Struct Biol 155:351–360. https://doi.org/10.1016/j.jsb.2006.02.016 CrossRefPubMed

25.

Wu Z, Wu L, Weng D et al (2009) Reduced expression of lamin A/C correlates with poor histological differentiation and prognosis in primary gastric carcinoma. J Exp Clin Cancer Res 28:8. https://doi.org/10.1186/1756-9966-28-8 CrossRefPubMedPubMedCentral

26.

Belt EJT, Fijneman RJA, van den Berg EG et al (2011) Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence. Eur J Cancer 47:1837–1845. https://doi.org/10.1016/j.ejca.2011.04.025 CrossRefPubMed

27.

Wazir U, Ahmed M, Bridger J et al (2013) The clinicopathological significance of lamin A/C, lamin B1 and lamin B receptor mRNA expression in human breast cancer. Cell Mol Biol Lett 18:595–611. https://doi.org/10.2478/s11658-013-0109-9 CrossRefPubMedPubMedCentral

28.

Matsumoto A, Hieda M, Yokoyama Y et al (2015) Global loss of a nuclear lamina component, lamin A/C, and LINC complex components SUN1, SUN2, and nesprin-2 in breast cancer. Cancer Med 4:1547–1557. https://doi.org/10.1002/cam4.495 CrossRefPubMedPubMedCentral

29.

Capo-chichi CD, Cai KQ, Smedberg J et al (2011) Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. Chin J Cancer 30:415–425CrossRefPubMedPubMedCentral

30.

Aljada A, Doria J, Saleh AM et al (2016) Altered Lamin A/C splice variant expression as a possible diagnostic marker in breast cancer. Cell Oncol 39:161–174. https://doi.org/10.1007/s13402-015-0265-1 CrossRef

31.

Abd El-Rehim DM, Ball G, Pinder SE et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350. https://doi.org/10.1002/ijc.21004 CrossRefPubMed

32.

Kollias J, Murphy CA, Elston CW et al (1999) The prognosis of small primary breast cancers. Eur J Cancer 35:908–912CrossRefPubMed

33.

Madjd Z, Pinder SE, Paish C et al (2003) Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 200:633–639. https://doi.org/10.1002/path.1357 CrossRefPubMed

34.

Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252–7259CrossRef

35.

Agrelo R, Setien F, Espada J et al (2005) Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. J Clin Oncol 23:3940–3947. https://doi.org/10.1200/JCO.2005.11.650 CrossRefPubMed

36.

Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163–167. https://doi.org/10.1038/5947 CrossRefPubMed

37.

Baylin SB, Esteller M, Rountree MR et al (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10:687–692CrossRefPubMed

38.

Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21:5462–5482. https://doi.org/10.1038/sj.onc.1205606 CrossRefPubMed

39.

Yan PS, Venkataramu C, Ibrahim A et al (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12:6626–6636. https://doi.org/10.1158/1078-0432.CCR-06-0467 CrossRefPubMed

40.

Cheng ASL, Culhane AC, Chan MWY et al (2008) Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res 68:1786–1796. https://doi.org/10.1158/0008-5472.CAN-07-5547 CrossRefPubMedPubMedCentral

41.

Sunami E, Shinozaki M, Sim MS et al (2008) Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 10:R46. https://doi.org/10.1186/bcr2098 CrossRefPubMedPubMedCentral

42.

Jing F, Yuping W, Yong C et al (2010) CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol 31:321–331. https://doi.org/10.1007/s13277-010-0040-x CrossRefPubMed

43.

Karray-Chouayekh S, Trifa F, Khabir A et al (2010) Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol 136:203–210. https://doi.org/10.1007/s00432-009-0649-6 CrossRefPubMed

44.

Sharma G, Mirza S, Parshad R et al (2010) Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci 87:83–91. https://doi.org/10.1016/j.lfs.2010.05.001 CrossRefPubMed

45.

Swift-Scanlan T, Vang R, Blackford A et al (2011) Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther 11:853–865CrossRefPubMedPubMedCentral

46.

Irianto J, Pfeifer CR, Ivanovska IL et al (2016) Nuclear lamins in cancer. Cell Mol Bioeng 9:258–267. https://doi.org/10.1007/s12195-016-0437-8 CrossRefPubMedPubMedCentral

47.

Ferguson AT, Lapidus RG, Baylin SB, Davidson NE (1995) Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55:2279–2283PubMed

48.

Momparler RL, Bovenzi V (2000) DNA methylation and cancer. J Cell Physiol 183:145–154. https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291097-4652%28200005%29183%3A2%3C145%3A%3AAID-JCP1%3E3.0.CO%3B2-V CrossRefPubMed

49.

Tommasi S, Karm DL, Wu X et al (2009) Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res 11:R14. https://doi.org/10.1186/bcr2233 CrossRefPubMedPubMedCentral

50.

Yang L, Guan T, Gerace L (1997) Lamin-binding fragment of LAP2 inhibits increase in nuclear volume during the cell cycle and progression into S phase. J Cell Biol 139:1077–1087CrossRefPubMedPubMedCentral

Title: Expression of Lamin A/C in early-stage breast cancer and its prognostic value
Authors: I. M. Alhudiri
C. C. Nolan
I. O. Ellis
A. Elzagheid
E. A. Rakha
Andrew R. Green
C. J. Chapman
Publication date: 01-04-2019
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-05092-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Clinical implications of germline mutations in breast cancer genes: RECQL

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior

A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types

Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer